Bivalirudin With Provisional Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Primary Angioplasty in the Setting of Cardiogenic Shock

American Journal of Cardiology

Volumn 102, Issue 3, 2008, Pages 287-291

  Bonello, Laurent ^a   De Labriolle, Axel ^a   Roy, Probal ^a   Steinberg, Daniel H ^a   Pinto Slottow, Tina L ^a   Xue, Zhenyi ^a   Smith, Kimberley ^a   Torguson, Rebecca ^a   Suddath, William O ^a   Satler, Lowell F ^a   Kent, Kenneth M ^a   Pichard, Augusto D ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; ANGIOPLASTY; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CARDIOGENIC SHOCK; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOMA; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY ANGIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HIRUDINS; HUMANS; INTEGRIN BETA3; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PLATELET MEMBRANE GLYCOPROTEIN IIB; RECOMBINANT PROTEINS; SHOCK, CARDIOGENIC; TREATMENT OUTCOME;

EID: 51749103330     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.03.052     Document Type: Article

References (25)

1. Giri S., Mitchel J., Azar R.R., Kiernan F.J., Fram D.B., McKay R.G., Mennett R., Clive J., and Hirst J.A. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 89 (2002) 126-131
2. Stone GW for the Horizon AMI Investigators. A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction-30 Day Results (2007) Presented at Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC.
3. Stone G.W., Ware J.H., Bertrand M.E., Lincoff A.M., Moses J.W., Ohman E.M., White H.D., Feit F., Colombo A., McLaurin B.T., et al., ACUITY Investigators. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 298 (2007) 2497-2506
4. Lincoff A.M., Bittl J.A., Harrington R.A., Feit F., Kleiman N.S., Jackman J.D., Sarembock I.J., Cohen D.J., Spriggs D., Ebrahimi R., et al., REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
5. Hochman J.S., Boland J., Sleeper L.A., Porway M., Brinker J., Col J., Jacobs A., Slater J., Miller D., Wasserman H., et al., SHOCK Registry Investigators. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: results of an International Registry. Circulation 91 (1995) 873-881
6. Antman E.M., Anbe D.T., Armstrong P.W., Bates E.R., Green L.A., Hand M., Hochman J.S., Krumholz H.M., Kushner F.G., Lamas G.A., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). J Am Coll Cardiol 44 (2004) e1-e211
7. Wolfram R., Leborgne L., Cheneau E., Pinnow E.E., Canos D.A., Hellinga D., Satler L.F., Pichard A.D., Kent K.M., and Waksman R. Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention. Am J Cardiol 92 (2003) 1080-1083
8. Lincoff A.M., Kleiman N.S., Kereiakes D.J., Feit F., Bittl J.A., Jackman J.D., Sarembock I.J., Cohen D.J., Spriggs D., Ebrahimi R., et al., REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 292 (2004) 696-703
9. Weitz J.I., Hudoba M., Massel D., Maraganore J., and Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 86 (1990) 385-391
10. Eitzman D.T., Chi L., Saggin L., Schwartz R.S., Lucchesi B.R., and Fay W.P. Heparin neutralization by platelet-rich thrombi: role of platelet factor 4. Circulation 89 (1994) 1523-1529
11. Hirsh J., Raschke R., Warkentin T.E., Dalen J.E., Deykin D., and Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 108 (1995) 258S-275S
12. Aggarwal A., Sobel B.E., and Schneider D.J. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. J Thromb Thrombolysis 13 (2002) 161-165
13. Anand S.X., Kim M.C., Kamran M., Sharma S.K., Kini A.S., Fareed J., Hoppensteadt D.A., Carbon F., Cavusoglu E., Varon D., et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol 100 (2007) 417-424
14. Schneider D.J., Keating F., and Sobel B.E. Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation. Coron Artery Dis 17 (2006) 471-476
15. Butenas S., Orfeo T., Brummel-Ziedins K.E., and Mann K.G. Influence of bivalirudin on tissue factor-triggered coagulation. Blood Coagul Fibrinolysis 18 (2007) 407-414
16. Geppert A., Dorninger A., Delle-Karth G., Zorn G., Heinz G., and Huber K. Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med 34 (2006) 2035-2042
17. Schmidt H., Hennen R., Keller A., Russ M., Müller-Werdan U., Werdan K., and Buerke M. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med 32 (2006) 1248-1251
18. Harding S.A., Din J.N., Sarma J., Josephs D.H., Fox K.A., and Newby D.E. Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin. Heart 92 (2006) 1635-1638
19. Li G., Keenan A.C., Young J.C., Hall M.J., Pamuklar Z., Ohman E.M., Steinhubl S.R., and Smyth S.S. Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol 27 (2007) 1850-1856
20. Keating F.K., Dauerman H.L., Whitaker D.A., Sobel B.E., and Schneider D.J. Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res 118 (2006) 361-369
21. Busch T., Sîrbu H., Zenker D., and Dalichau H. Vascular complications related to intraaortic balloon counterpulsation: an analysis of ten years experience. Thorac Cardiovasc Surg 45 (1997) 55-59
22. Berry C., Norrie J., Hogg K., Brett M., Stevenson K., and McMurray J.J. The prevalence, nature, and importance of hematologic abnormalities in heart failure. Am Heart J 151 (2006) 1313-1321
23. Schiller G.J., and Berkman S.A. Hematologic aspects of renal insufficiency. Blood Rev 3 (1989) 141-146
24. Moscucci M., Fox K.A., Cannon C.P., Klein W., López-Sendón J., Montalescot G., White K., and Goldberg R.J. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 (2003) 1815-1823
25. Shander A. Anemia in the critically ill. Crit Care Clin 20 (2004) 159-178